Dose‐dependent inhibition of CYP3A activity by clarithromycin during Helicobacter pylori eradication therapy assessed by changes in plasma lansoprazole levels and partial cortisol clearance to 6β‐hydroxycortisol
Authors: Ushiama Hideki , Echizen Hirotoshi , Nachi Shinobu , Ohnishi Akihiro 
Published: October 2002

Objective

A 7‐day triple therapy with lansoprazole, amoxicillin (INN, amoxicilline), and clarithromycin is widely used for eradication of Helicobacter pylori. Because clarithromycin is a potent inhibitor of cytochrome P450 (CYP) 3A, we investigatedwhether the standard triple therapy with clarithromycin would elicit clinically relevant CYP3A inhibition and alter CYP3A‐mediated lansoprazole disposition in H pylori‐positive patients.

Methods

Twenty H pylori‐positive patients with peptic ulcer disease were randomly assigned to 2 groups: One group received 200 mg clarithromycin, 30 mg lansoprazole, and 750 mg amoxicillin at 8 am and 8 pm for 7 days; the other group received 400 mg clarithromycin, 30 mg lansoprazole, and 750 mg amoxicillin at 8 am and 8 pm for 7 days. Ten healthy control subjects received 30 mg lansoprazole and 750 mg amoxicillin at 8 amand 8 pm for 7 days but did not receive clarithromycin. Urine samples were collected for 3 hours (from 8 am to 11 am) for urinary 6β‐hydroxycortisol and cortisol assay, and midpoint (at 9:30 am) plasma samples for cortisol assay were obtained from all participants before the drug therapy (day 0) and on day 7. In vivo CYP3A activity was assessed by the partial cortisol clearance by means of the formation of 6β‐hydroxycortisol (CLcortisol→6β‐hydroxycortisol) and the urinary 6β‐hydroxycortisol/cortisol ratio. Additional plasma samples for lansoprazole, 5‐hydroxylansoprazole, and lansoprazole sulfone assay were obtained at 11 am on day 7.

Results

The groups of patients given 400 and 800 mg/day clarithromycin for H pylori eradication therapy showed 39% (from 2.20 ± 1.29 to 1.35 ± 0.88 mL/min [day 0 versus 7, mean ± SD]; P < .05) and 68%(2.40 ± 1.22 to 0.76 ± 0.51 mL/min; P < .05) reductions in CLcortisol→6β‐hydroxycortisol, respectively. In contrast, the control subjects given lansoprazole and amoxicillin without clarithromycin showed no significant changes in CLcortisol→6β‐hydroxycortisol. The urinary 6β‐hydroxycortisol/cortisol ratio also decreased significantly (P < .05) in the patient groups but not in the control subjects. The mean 3‐hour plasma lansoprazole levels elevated in proportion to the doses of clarithromycin: 385 ± 338 ng/mL for the control subjects, 696 ± 797 ng/mL for the H pylori‐positive patients given 400 mg/day clarithromycin, and 947 ± 806 ng/mL for the H pylori‐positive patients given 800 mg/day clarithromycin (P < .05 versus the control subjects). No significant differences were observed among the groups in the mean plasma ratios of 5‐hydroxylansoprazole or lansoprazole sulfone to lansoprazole.

Conclusions

The 7‐day H pylori eradication therapy with clarithromycin, amoxicillin, and lansoprazole may elicit substantial inhibition of in vivo CYP3A activity. Although resultant elevations in plasma lansoprazole concentrations may be beneficialfor H pylori eradication, caution must be exercised for possible drug interaction with a concomitantly administered CYP3A substrate (s) in patients undergoing H pylori eradication therapy with clarithromycin, amoxicillin, and lansoprazole.

Clinical Pharmacology & Therapeutics (2002) 72, 33–43; doi: 10.1067/mcp.2002.125559